A multicenter international controlled comparison of two dosage regimes of misoprostol and cimetidine in the treatment of duodenal ulcer in out-patients
- P. A. NicholsonAffiliated withClinical Research and Medical Affairs Europe, G.D. Searle & Co. Ltd.
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
In this double-blind parallel group multicenter international study, patients with endoscopically proven acute duodenal ulcers were allocated randomly to treatment for four weeks with either misoprostol 50 μg, misoprostol 200 μg or cimetidine 300 mg, each given q.i.d.. Endoscopic, clinical and laboratory assessments were made prior to and after four weeks' treatment. A clinical assessment was also made at two weeks. 703 patients were recruited. The three treatment groups were similar with regard to age, sex and occupation. Therapeutic success was defined as complete healing of all ulcers on the basis of an endoscopic examination. On an intent to treat basis, which includes all losses to follow-up and withdrawals as treatment failures, the cure rates in the misoprostol 50 μg, misoprostol 200 μg and cimetidine groups were 41%, 60% and 67% respectively. There was no statistically significant difference between the misoprostol 200 μg and the cimetidine 300 mg groups (P=0.11). Both were significantly better than the low dose misoprostol group (P<0.001). All three treatments were well tolerated and severe adverse events were rare.
- A multicenter international controlled comparison of two dosage regimes of misoprostol and cimetidine in the treatment of duodenal ulcer in out-patients
Digestive Diseases and Sciences
Volume 30, Issue 11 Supplement, pp 171S-177S
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers-Plenum Publishers
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Clinical Research and Medical Affairs Europe, G.D. Searle & Co. Ltd., High Wycombe, Buckinghamshire, UK